This is the first report about the efficacy and safety of a therapy consisting of intralesional injections of infliximab for a granulomatous skin disease. Although this approach was clearly effective for necrobiosis lipoidica, the disease recurred several months after treatment interruption, raising the question of the need for maintenance therapy. Further controlled long-term trials are thus necessary.
No takes yet. Share an insight, caveat, or question.
Barde et al. (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: